GlassScriptPhysician profile
Allison Rostocki
NPI 1396170320
$7,389.04
in general payments reported to CMS, 2019-2025
28 companies · $830 in 2025
The $830 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $2,730 · 2023: $2,746 · 2024: $590 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $883.67 | 2021-2024 | Xarelto |
| Amgen INC. | $822.63 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $644.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $622.48 | 2021-2023 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $615.21 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.18 | 2021-2025 | Jardiance |
| Pfizer INC. | $553.55 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $347.72 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $284.62 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $221.86 | 2024-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $217.93 | 2022-2024 | Opsumit, Uptravi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.21 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $149.49 | 2022-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.56 | 2023 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $94.01 | 2022-2023 | Amvuttra, Onpattro |
| Amarin Pharma, INC. | $88.35 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $84.49 | 2022-2024 | Livalo |
| Argenx US, INC. | $82.98 | 2023 | Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $75.02 | 2021 | |
| Inspire Medical Systems, INC. | $73.65 | 2023 | Inspire |
| Scpharmaceuticals INC. | $70.35 | 2025 | |
| Abiomed | $69.72 | 2023 | Impella |
| Esperion Therapeutics, INC. | $67.88 | 2022-2024 | Nexletol |
| Ferring Pharmaceuticals INC. | $36.16 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.75 | 2023 | Evkeeza |
| Abbvie INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rostocki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.